Brevan Howard Capital Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Brevan Howard Capital Management’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$230K	Buy	+34,767	New	+$240K	﹤0.01%	1845

Other funds holding EPRX

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Brevan Howard Capital Management's EPRX Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 34,767 shares worth $230K. The stake represents ﹤0.01% of the portfolio and ranks #1845 among its holdings.

68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

Brevan Howard Capital Management held 34,767 shares of Eupraxia Pharmaceuticals worth $230K as of Q2 2026.
Eupraxia Pharmaceuticals was a new Brevan Howard Capital Management position in Q2 2026.
Eupraxia Pharmaceuticals made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1845 holding.
68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.